September 1, 2011

Press Release

Mitsubishi Tanabe Pharma Corporation

New Drug Application Filed in Japan for MP-513
a Type 2 Diabetes Treatment

Osaka, Japan, September 1, 2011---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced that the Company filed to the Ministry of Health, Labor and Welfare an application for the manufacturing and marketing approval of MP-513 (generic name: teneligliptin), a type 2 diabetes treatment that has been developed in Japan.

MP-513 is an oral type 2 diabetes treatment that has been created by Mitsubishi Tanabe Pharma. It controls blood glucose levels by inhibiting the function of dipeptidyl peptidase-4 (DPP-4) that selectively decomposes glucagon-like peptide-1 (GLP-1), a hormone secreted from the gastrointestinal tract in response to food intake, to promote insulin secretion and suppress glucagon secretion. With its potent and sustained action and remarkable feature of being unlikely to cause hypoglycemia and unwanted weight gain, problematic side effects of conventional diabetic remedies, MP-513 is expected to be efficient in ameliorating hyperglycemia by once-a-day oral administration. Having a low renal excretion rate, the drug is expected to be a DPP-4 inhibitor that is readily useful for patients with impaired renal function.

Mitsubishi Tanabe Pharma makes efforts to achieve early approval and launch of the drug, and will contribute to improving drug therapy for type 2 diabetics in Japan through supplying MP-513.

<<Contact for Inquiries>>
Corporate Communications Department
Phone: +81-6-6205-5211